Western European Journal of Medicine and Medical Science
Volume 3, Issue 10, October 2025
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed


# Aspergillosis.

**Komilova Nafisa Karimovna**
Republican Specialized Scientific and Practical Medical Center for Epidemiology, Microbiology, Infectious and Parasitic Diseases
Doctor.
Infectious diseases

**Annotation:** Aspergillosis is a spectrum of diseases caused by fungi of the genus Aspergillus, ranging from allergic reactions and chronic lung disease to fulminant invasive infections in immunocompromised hosts. The diagnosis is challenging due to nonspecific signs and imperfect diagnostic tests, and treatment is complicated by drug toxicity, interactions, and emerging resistance. This article reviews the current literature, presents typical diagnostic and analytic methods, and outlines findings, discussion, and recommendations for future research and clinical care.
**Keywords:** Aspergillosis; Aspergillus fumigatus; invasive pulmonary aspergillosis; chronic pulmonary aspergillosis; allergic bronchopulmonary aspergillosis; diagnosis; antifungal therapy; prognostic factors

Aspergillosis is a spectrum of diseases caused by Aspergillus, a genus of mold (filamentous fungi) commonly found in the environment, including soil, decaying vegetation, indoor dust, and air. The mold produces microscopic spores that can be inhaled, potentially leading to infection or allergic reactions, particularly in susceptible individuals. Aspergillosis manifests in various forms, ranging from mild allergic reactions to life-threatening invasive infections, depending on the individual□s immune status and underlying health conditions. Below is a detailed exploration of aspergillosis, covering its types, causes, risk factors, symptoms, diagnosis, treatment, prevention, and prognosis.

Types of Aspergillosis

Aspergillosis presents in distinct clinical forms, each with unique characteristics:

Allergic Bronchopulmonary Aspergillosis (ABPA):

- Description: ABPA is an allergic reaction to Aspergillus antigens in the lungs, primarily affecting individuals with asthma or cystic fibrosis. It is not an invasive infection but an exaggerated immune response causing airway inflammation.
- Pathophysiology: Inhaled Aspergillus spores trigger a hypersensitivity reaction (Type I and Type III immune responses), leading to mucus production, airway obstruction, and bronchiectasis (widening of airways).
- Prevalence: Most common in people with chronic lung conditions; estimated to affect 2□15% of cystic fibrosis patients and 1□2% of asthma patients.
- Symptoms: Wheezing, cough (often with mucus plugs), shortness of breath, recurrent chest infections, and low-grade fever. Severe cases may lead to lung scarring.

Chronic Pulmonary Aspergillosis (CPA):

- Description: A chronic, progressive lung infection caused by Aspergillus, typically in individuals with pre-existing lung damage (e.g., from tuberculosis, COPD, or sarcoidosis). It includes subtypes like chronic cavitary pulmonary aspergillosis (CCPA) and chronic fibrosing pulmonary aspergillosis.
- Pathophysiology: The fungus colonizes damaged lung tissue or cavities, forming fungal masses or cavities without widespread invasion.

Western European Journal of Medicine and Medical Science
Volume 3, Issue 10, October 2025
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed


- Prevalence: Less common than ABPA but significant in patients with lung diseases; exact prevalence is hard to estimate due to underdiagnosis.
- Symptoms: Chronic cough (sometimes productive), hemoptysis (coughing up blood), weight loss, fatigue, chest pain, and shortness of breath. Symptoms develop slowly over months or years.

Invasive Aspergillosis (IA):

- Description: A severe, life-threatening infection where Aspergillus invades lung tissue and potentially spreads to other organs (e.g., brain, heart, kidneys). It primarily affects immunocompromised individuals.
- Pathophysiology: The fungus invades blood vessels, causing tissue necrosis and systemic spread. Common in patients with prolonged neutropenia (low neutrophil counts), organ transplants, or advanced HIV/AIDS.
- Prevalence: Rare in healthy individuals but significant in high-risk groups (e.g., 5□10% of hematopoietic stem cell transplant recipients).
- Symptoms: Fever (often unresponsive to antibiotics), chest pain, cough, hemoptysis, shortness of breath, and systemic symptoms (e.g., confusion, seizures) if the infection spreads.

Aspergilloma (Fungus Ball):

- Description: A fungal ball formed by Aspergillus growing in a pre-existing lung cavity (e.g., from prior tuberculosis or sarcoidosis). It is usually localized and non-invasive.
- Pathophysiology: The fungus colonizes a lung cavity, forming a tangled mass of fungal hyphae, mucus, and debris.
- Prevalence: Uncommon, often found incidentally on imaging in patients with prior lung disease.
- Symptoms: Often asymptomatic, but may cause hemoptysis (ranging from mild to life-threatening), cough, or chest discomfort.

Other Forms:

- Cutaneous Aspergillosis: Rare, occurs when Aspergillus infects the skin, usually at sites of injury or IV catheter insertion in immunocompromised patients.
- Sinus Aspergillosis: Can present as allergic fungal sinusitis (similar to ABPA) or invasive sinus infection, causing nasal congestion, sinus pain, or facial swelling.
- Otomycosis: Aspergillus infection of the ear canal, causing itching, pain, or discharge.

Causes and Risk Factors

Aspergillus species (notably A. fumigatus, A. flavus, A. niger, and A. terreus) are ubiquitous in the environment. Spores are inhaled daily by most people without issue, as healthy immune systems clear them effectively. However, certain conditions increase the risk of aspergillosis:

- Immunosuppression:
  - Prolonged neutropenia (e.g., from chemotherapy or leukemia).
  - Organ or stem cell transplantation.
  - Advanced HIV/AIDS or other immunodeficiencies.
  - Long-term use of immunosuppressive drugs (e.g., corticosteroids, biologics).
- Underlying Lung Conditions:
  - Asthma or cystic fibrosis (for ABPA).
  - COPD, tuberculosis, sarcoidosis, or lung cancer (for CPA or aspergilloma).
- Environmental Exposure:
  - High exposure to Aspergillus spores in moldy environments (e.g., compost piles, construction sites, damp buildings).

Western European Journal of Medicine and Medical Science
Volume 3, Issue 10, October 2025
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed


- Occupational exposure (e.g., farmers, construction workers).
- Other Factors:
  - Hospitalization, especially in intensive care units (ICUs).
  - Chronic illnesses like diabetes or liver disease.
  - Genetic predispositions (e.g., mutations affecting immune response in cystic fibrosis).

Symptoms

Symptoms vary widely by type and patient health:

- ABPA: Wheezing, productive cough (brownish mucus plugs), shortness of breath, fatigue, recurrent asthma exacerbations, low-grade fever.
- CPA: Chronic cough (often with blood), weight loss, fatigue, night sweats, chest pain, progressive shortness of breath.
- Invasive Aspergillosis: High fever, chest pain, dry or productive cough, hemoptysis, shortness of breath, and organ-specific symptoms (e.g., seizures, stroke-like symptoms if the brain is affected).
- Aspergilloma: Often asymptomatic; when symptomatic, hemoptysis (mild to severe), cough, or chest discomfort.
- Sinus or Cutaneous Forms: Nasal congestion, sinus pain, skin lesions (red, painful, or ulcerated), or ear symptoms (itching, discharge).

Diagnosis

Diagnosing aspergillosis is challenging due to its varied presentations and overlap with other conditions. A combination of clinical, imaging, and laboratory findings is used:

Clinical Evaluation:

- Detailed medical history (e.g., immune status, lung disease, environmental exposure).
- Assessment of symptoms and risk factors.

Imaging:

- Chest X-ray or CT Scan: Detects abnormalities like nodules, cavities, or the □halo sign□ (in invasive aspergillosis, indicating tissue invasion).
- CT Sinus or Brain: For sinus or central nervous system involvement.
- Aspergilloma may show a □fungus ball□ (mobile mass in a lung cavity).

Laboratory Tests:

- Sputum Culture: Identifies Aspergillus in sputum, though not always specific.
- Blood Tests:
  - Galactomannan assay (detects fungal cell wall component, useful for invasive aspergillosis).
  - Aspergillus-specific IgE or IgG (elevated in ABPA or CPA).
- Bronchoalveolar Lavage (BAL): Fluid from lungs tested for Aspergillus.
- Biopsy: Tissue sampling (e.g., lung, sinus) for definitive diagnosis, showing fungal hyphae.

**Conclusion**

Aspergillosis is a diverse group of diseases caused by Aspergillus mold, with presentations ranging from allergic reactions to life-threatening infections. Early diagnosis and tailored treatment are critical, especially for invasive forms. Management involves antifungals, supportive care, and addressing underlying conditions. Preventive measures are essential for high-risk individuals.

Aspergillosis remains a clinically formidable infection with a wide spectrum from allergic to invasive disease. Diagnosis is often delayed due to suboptimal sensitivity of tests and non-specific clinical features. Mortality of invasive disease remains high despite current antifungal

Western European Journal of Medicine and Medical Science
Volume 3, Issue 10, October 2025
https://westerneuropeanstudies.com/index.php/3
ISSN (E): 2942-1918 Open Access| Peer Reviewed


therapies. There is a tension between strict consensus definitions and real-world disease, as nonconsensus treated cases may fare as poorly as consensus cases. Progress in diagnostics, therapeutics, and clinical research is essential to improve outcomes.

**References.**

1. Kousha, M., Tadi, R., & Soubani, A. O. (2011). *Pulmonary aspergillosis: a clinical review*. **European Respiratory Review**, 20(121), 156-174. publications.ersnet.org
2. Denning, D. W. (2009). *Aspergillosis*. **New England Journal of Medicine**, 360(18), 1870-1884. New England Journal of Medicine
3. Machado, M., Pasqualotto, A. C., de Souza, R. P., & others. (2024). *Invasive aspergillosis: A comprehensive review*. (ScienceDirect). ScienceDirect
4. Epelbaum, O., & others. (2025). *Treatment of Invasive Pulmonary Aspergillosis and Recommendations*. American Thoracic Society / Respiratory Care context. ATS Journals
5. Swu-Jane Lin et al. (2001). *Aspergillosis Case-Fatality Rate: Systematic Review of the Literature*. Clin Infect Dis. OUP Academic
6. A Systematic Review of Chronic Pulmonary Aspergillosis Among Patients With Tuberculosis (2024). (Clinical Infectious Diseases). OUP Academic
7. Elkhapery, A. et al. (2025). *Emerging Risk Factors for Invasive Pulmonary Aspergillosis*. (PMC) PMC
8. Diagnosis of invasive pulmonary aspergillosis using metagenomic sequencing (2024). On new diagnostic molecular approach. PMC